Therefore, a combination therapy of anti-PD-L1 antibodies and NK cells can significantly enhance the antitumor effect, improve the survival benefit, and serve as new treatment regimen for previously treated patients with advanced PD-L1+ NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.